GOP-1 inhibitors like ozempic and Magaro, originally developed as type two diabetes drugs, are now being recognized for significant weight loss benefits. This weight loss trend is predicted to lower flight costs due to reduced overall weight, leading major retailers to anticipate decreased snack consumption. The evolution of these drugs demonstrates a shift towards focusing on weight loss rather than glucose control.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode